» Articles » PMID: 19390859

Synaptic Degeneration in Alzheimer's Disease

Overview
Specialty Neurology
Date 2009 Apr 25
PMID 19390859
Citations 250
Authors
Affiliations
Soon will be listed here.
Abstract

Synaptic loss is the major neurobiological substrate of cognitive dysfunction in Alzheimer's disease (AD). Synaptic failure is an early event in the pathogenesis that is clearly detectable already in patients with mild cognitive impairment (MCI), a prodromal state of AD. It progresses during the course of AD and in most early stages involves mechanisms of compensation before reaching a stage of decompensated function. This dynamic process from an initially reversible functionally responsive stage of down-regulation of synaptic function to stages irreversibly associated with degeneration might be related to a disturbance of structural brain self-organization and involves morpho-regulatory molecules such as the amyloid precursor protein. Further, recent evidence suggests a role for diffusible oligomers of amyloid beta in synaptic dysfunction. To form synaptic connections and to continuously re-shape them in a process of ongoing structural adaptation, neurons must permanently withdraw from the cell cycle. Previously, we formulated the hypothesis that differentiated neurons after having withdrawn from the cell cycle are able to use molecular mechanisms primarily developed to control proliferation alternatively to control synaptic plasticity. The existence of these alternative effector pathways within neurons might put them at risk of erroneously converting signals derived from plastic synaptic changes into the program of cell cycle activation, which subsequently leads to cell death. The molecular mechanisms involved in cell cycle activation might, thus, link aberrant synaptic changes to cell death.

Citing Articles

YOD1 regulates microglial homeostasis by deubiquitinating MYH9 to promote the pathogenesis of Alzheimer's disease.

Sun J, Chen F, She L, Zeng Y, Tang H, Ye B Acta Pharm Sin B. 2025; 15(1):331-348.

PMID: 40041897 PMC: 11873648. DOI: 10.1016/j.apsb.2024.11.020.


Synaptic protein CSF levels relate to memory scores in individuals without dementia.

Wesenhagen K, de Leeuw D, Tomassen J, Gobom J, Bos I, Vos S Alzheimers Res Ther. 2025; 17(1):56.

PMID: 40033427 PMC: 11877693. DOI: 10.1186/s13195-025-01703-z.


Identification of a novel pyrrolo[2,3-]pyridine compound as a potent glycogen synthase kinase 3β inhibitor for treating Alzheimer's disease.

Xun Q, Zhang J, Feng L, Ma Y, Li Y, Shi X J Enzyme Inhib Med Chem. 2025; 40(1):2466846.

PMID: 39976249 PMC: 11843656. DOI: 10.1080/14756366.2025.2466846.


Human and mouse proteomics reveals the shared pathways in Alzheimer's disease and delayed protein turnover in the amyloidome.

Yarbro J, Han X, Dasgupta A, Yang K, Liu D, Shrestha H Nat Commun. 2025; 16(1):1533.

PMID: 39934151 PMC: 11814087. DOI: 10.1038/s41467-025-56853-3.


Neurophysiological markers of early cognitive decline in older adults: a mini-review of electroencephalography studies for precursors of dementia.

Tanaka M, Yamada E, Mori F Front Aging Neurosci. 2024; 16:1486481.

PMID: 39493278 PMC: 11527679. DOI: 10.3389/fnagi.2024.1486481.